Skip to main content

European Pediatric Neurology Society (EPNS), 2025

Filter
Close
Content type:
Safety, tolerability, pharmacokinetics, and efficacy of fenfluramine in combination with cannabidiol: results from an exploratory phase 1 study
Rebecca Zhang Roper, Aravind Mittur, Brooks Boyd, et al.
Non-seizure benefits of long-term fenfluramine treatment in pediatric patients with Dravet syndrome
Cathrine E. Gjerulfsen, Anne V. Jakobsen, Marina Nikanorova, et al.
Fenfluramine efficacy trajectories in placebo or treatment groups from randomized controlled trial to open-label extension in patients with Lennox-Gastaut Syndrome
Lieven Lagae, Rima Nabbout, Orrin Devinsky, et al.
Onset and duration of adverse events in patients treated with fenfluramine in the Lennox-Gastaut Syndrome clinical trials
Lieven Lagae, Joseph Sullivan, Raman Sankar, et al.
Safety and effectiveness of fenfluramine for the treatment of seizures in Lennox-Gastaut Syndrome: results from the final analysis of an open-label extension study
An-Sofie Schoonjans, Kelly G. Knupp, Ingrid E. Scheffer, et al.
Prospective evaluation of non-seizure benefits related to treatment with fenfluramine in pediatric and adult patients with Dravet syndrome
Cathrine E. Gjerulfsen, Anne V. Jakobsen, Marina Nikanorova, et al.
Antiseizure medication regimen adjustment after fenfluramine initiation: lessons learned from European early access program in pediatric and adult patients with Dravet syndrome
Milka Pringsheim, Renzo Guerrini, Ángel Aledo-Serrano, et al.
Use of fenfluramine and cannabidiol in daily practice: a retrospective analysis of German prescription claims
Milka Pringsheim, Felix von Podewils, Claudio Schiener, et al.
Brivaracetam adjunctive therapy in pediatric and adult patients with focal-onset seizures in mid-European countries: 12-month, real-world outcomes from the BRIVA-REG study
Zafeiriou Dimitrios, Vasilios K Kimiskidis, András Fogarasi, et al.